NT-101 / NexThera - LARVOL DELTA

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: NexThera Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NexThera Completes First Patient Enrollment in U.S. Clinical Trial for ‘NT-101,’ an Eye Drop Treatment for Wet AMD (Businesswire) - "NexThera...announced on April 9th that it has completed the first patient enrollment for its Phase 1/2a clinical trial of NT-101, a novel eye drop treatment for wet AMD, at a clinical trial site in Pennsylvania on April 8th....This clinical trial will enroll a total of 30 wet AMD patients across four clinics in Maryland, Philadelphia, North Carolina, and Texas. The main goal is to assess the safety and tolerability of NT-101.... In the clinical trial, patients will receive either a low-dose or high-dose of NT-101 twice daily, in the morning and evening, for 4 weeks. This will be succeeded by a 4-week follow-up, making the total duration 8 weeks."

Trial status • Wet Age-related Macular Degeneration

NT-101 Topical Ophthalmic Solution in Patients with Wet AMD (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: NexThera Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration